BACKGROUND: Effective long-term chemotherapy yielding good quality of life is essential. The clinical benefits of oral UFT and cyclophosphamide (CPA) combination chemotherapy for metastatic breast cancer (MBC) were evaluated. PATIENTS AND METHODS: Twenty cases with MBC were enrolled. The mean age was 54 years. Five cases had loco-regional and others had distant metastasis. Nineteen cases had previous therapies. Daily treatment consisted of UFT (300 to 400 mg/body) and CPA (100 to 150 mg/body), both given orally. RESULTS: The treatment period ranged from 4 to 80 weeks. The response rate was 35%, while it was 65% in the "stable disease > 6 months" category. The mean time to the first sign of response was 7 weeks and the time to tumor progression was 37 weeks. The frequent adverse effects were leukocytopenia (55%) and gastrointestinal symptoms (35%). The incidence of adverse grade > or = 3 effects was 25%. CONCLUSION: Oral UFT and CPA combination chemotherapy may be suitable for MBC.
BACKGROUND: Effective long-term chemotherapy yielding good quality of life is essential. The clinical benefits of oral UFT and cyclophosphamide (CPA) combination chemotherapy for metastatic breast cancer (MBC) were evaluated. PATIENTS AND METHODS: Twenty cases with MBC were enrolled. The mean age was 54 years. Five cases had loco-regional and others had distant metastasis. Nineteen cases had previous therapies. Daily treatment consisted of UFT (300 to 400 mg/body) and CPA (100 to 150 mg/body), both given orally. RESULTS: The treatment period ranged from 4 to 80 weeks. The response rate was 35%, while it was 65% in the "stable disease > 6 months" category. The mean time to the first sign of response was 7 weeks and the time to tumor progression was 37 weeks. The frequent adverse effects were leukocytopenia (55%) and gastrointestinal symptoms (35%). The incidence of adverse grade > or = 3 effects was 25%. CONCLUSION: Oral UFT and CPA combination chemotherapy may be suitable for MBC.
Authors: Giacomo Allegrini; Teresa Di Desidero; Maria Teresa Barletta; Anna Fioravanti; Paola Orlandi; Bastianina Canu; Silvio Chericoni; Fotios Loupakis; Antonello Di Paolo; Gianluca Masi; Andrea Fontana; Sara Lucchesi; Giada Arrighi; Mario Giusiani; Andrea Ciarlo; Giovanni Brandi; Romano Danesi; Robert S Kerbel; Alfredo Falcone; Guido Bocci Journal: Angiogenesis Date: 2012-03-02 Impact factor: 9.596